SFTPD and chronic obstructive pulmonary disease: These findings suggest that rfhSP-D has the potential to serve as a therapeutic agent for respiratory diseases characterized by decreased levels of SP-D and associated lung damage, offering promise for future treatment strategies in conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (118).